Homology Medicines is a genetic medicines company translating proprietary, cutting-edge gene editing and gene therapy technology into cures for patients with rare diseases.

The combination of a new multidimensional technology platform and a management team that has successfully developed and commercialized rare disease therapies uniquely positions us to move beyond the current limitations of gene editing and gene therapy approaches.

We have built foundational intellectual property on a family of gene editing and gene therapy vectors derived from naturally occurring human adeno-associated viruses (AAVs). Our technology is precise, on-target and highly efficient for in vivo editing of genetic mutations. Our unique technology and experienced team create a significant opportunity for us to rapidly advance a diverse pipeline of new medicines to cure genetic diseases.

Recent News

Homology Medicines to Present at the Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day

Homology Medicines Appoints Brad Smith as Chief Financial Officer

Homology Named Top 20 Life Science Startups to Watch in 2017

Team

Homology Medicines brings together leaders in rare diseases and genetic medicines to leverage our proprietary and powerful gene editing and gene therapy platform with one common goal: cure genetic disease.